机构:[1]Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China,[2]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China,[3]Department of GynecologicOncology, Shanxi Provincial Cancer Hospital, Taiyuan, China,[4]Department of Gynecology, Yanling Hospital of SouthernMedical University, Guangzhou, China,[5]Department of Obstetrics and Gynecology, Xijing Hospital of Airforce MedicalUniversity, Xi’an, China,[6]Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University,Zhengzhou, China,[7]Department of Gynecologic Oncology of Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou, China,河南省肿瘤医院[8]Department of Gynecology, The Forth Hospital of Hebei Medical University, Shijiazhuang, China,临床科室妇科河北医科大学第四医院[9]Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College,Beijing, China
Cervical cancer is the fourth most common cancer worldwide, but its incidence varies greatly in different countries. Regardless of incidence or mortality, the burden of cervical cancer in China accounts for approximately 18% of the global burden. The Chinese Cervical Cancer Clinical Study is a hospital-based multicenter open cohort. The major aims of this study include (i) to explore the associations of therapeutic strategies with complications as well as mid- and long-term clinical outcomes; (ii) to widely assess the factors which may have an influence on the prognosis of cervical cancer and then guide the treatment options, and to estimate prognosis using a prediction model for precise post-treatment care and follow-up; (iii) to develop a knowledge base of cervical clinical auxiliary diagnosis and prognosis prediction using artificial intelligence and machine learning approaches; and (iv) to roughly map the burden of cervical cancer in different districts and monitoring the trend in incidence of cervical cancer to potentially inform prevention and control strategies. Patients eligible for inclusion were those diagnosed with cervical cancer, whether during an outpatient visit or hospital admission, at 47 different types of medical institutions in 19 cities of 11 provinces across mainland China between 2004 and 2018. In a total, 63 926 patients with cervical cancer were enrolled in the cohort. Since the project inception, a large number of standardized variables have been collected, including epidemiological characteristics, cervical cancer-related symptoms, physical examination results, laboratory testing results, imaging reports, tumor biomarkers, tumor staging, tumor characteristics, comorbidities, co-infections, treatment and short-term complications. Follow-up was performed at least once every 6 months within the first 5 years after receiving treatment and then annually thereafter. At present, we are developing a cervical cancer imaging database containing Dicom files with data of computed tomography/magnetic resonance imaging examination. Additionally, we are also collecting original pathological specimens of patients with cervical cancer. Potential collaborators are welcomed to contact the corresponding authors, and anyone can submit at least one specific study proposal describing the background, objectives and methods of the study.
基金:
National Science and Technology
Support Program of China (2014BAI05B03), the National
Natural Science Fund of Guangdong (2015A030311024), the
Science and Technology Plan of Guangzhou (158100075),
Guangdong Medical Science and Technology Research Fund
Project (A2020077), Basic and Applied Basic Research Fund of
Guangdong Province (2019A1515110337), the Project
Supported by Guangdong Province Universities and Colleges
Pearl River Scholar Funded Scheme (2019), the Construction of
High-level University of Guangdong (G820332010, G618339167
and G618339164), Chinese Postdoctoral Science Foundation
(2019M660207), and Nanfang Hospital President Fund
(2019C005).
第一作者机构:[1]Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China,
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Zhang Xi-Ru,Li Zhi-Qiang,Sun Li-Xin,et al.Cohort Profile: Chinese Cervical Cancer Clinical Study[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.690275.
APA:
Zhang, Xi-Ru,Li, Zhi-Qiang,Sun, Li-Xin,Liu, Ping,Li, Zhi-Hao...&on behalf of Chinese Cervical Cancer Clinical Study collaborative group.(2021).Cohort Profile: Chinese Cervical Cancer Clinical Study.FRONTIERS IN ONCOLOGY,11,
MLA:
Zhang, Xi-Ru,et al."Cohort Profile: Chinese Cervical Cancer Clinical Study".FRONTIERS IN ONCOLOGY 11.(2021)